|18th December 2020||Jeryl L Hilleman||2,500||Open or private sale||$166.40||$416,000.00|
|16th December 2020||Joseph H. Reilly||3,228||Open or private sale||$2.64||$8,521.92|
|14th December 2020||Joseph H. Reilly||8,750||Exercise of derivative||$0.00|
|10th September 2020||Heek G Jan Van||7,000||Open or private purchase||$2.97||$20,790.00|
|31st July 2020||William F Doyle||896||Open or private sale||$76.39||$68,443.65|
|16th June 2020||Jeryl L Hilleman||8,797||Grant/award etc.||$0.00|
|10th June 2020||Jeryl L Hilleman||2,541||Grant/award etc.||$0.00|
|26th May 2020||Frederick W Ahlholm||8,339||Open or private sale||$15.00||$125,085.00|
|11th May 2020||William F Doyle||31,332||Open or private sale||$63.73||$1,996,725.70|
|8th May 2020||William F Doyle||31,903||Open or private sale||$63.50||$2,025,872.40|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho in 2007.